ELMSFORD, N.Y., June 16, 2020 /PRNewswire/ -- NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces Surface Acoustic Wave (SAW) based Ultrasonic Therapeutic Devices - the UroShield®, PainShield® and WoundShield®, today announced that its newly introduced PainShield PT 100 ultrasound therapy device has received the coveted Plus X Award 2020 in the categories of high quality, design, ease of use and functionality.
"Winning this award is a clear affirmation of the design, quality and innovation behind our PainShield technology," said Brian Murphy, CEO of NanoVibronix. "Millions of people suffer from chronic pain and now more than ever, clinicians and patients are looking for proven, non-pharmaceutical alternatives for pain management that can be administered in a variety of settings, especially the safety of a patient's home. Access to effective home care is critically important due to COVID-19 social distancing restrictions. PainShield PT 100 ultrasound therapy provides non-opioid pain therapy while maintaining social distancing at home and healthcare facilities. The nomination by Medisana and quality seals awarded by the panel at Plus X reinforce our confidence in the PainShield product and our optimism for accelerating market acceptance."
The new private label PainShield PT 100 ultrasound therapy device, which is sold directly and exclusively by Medisana outside the United States, is a portable therapeutic ultrasound device for the treatment of pain and soft tissue injuries. It works with ultrasound at low intensity and low frequency, thus improving local blood circulation, relieving local inflammation and accelerating the healing of connective tissue. The ultrasound therapy device is easy to use anywhere and anytime – at home, at work, in a clinical setting or even while sleeping – with comfortable, hands-free application. The Medisana PainShield PT 100 was designed specifically for the company to be sold throughout their extensive international network. The ultrasound therapy device enables the treatment of large body surfaces as well as areas that are difficult to access without the use of ultrasound gel.
About Plus X Award
The Plus X Award is the world's largest innovation award for technology, sports and lifestyle. The award honors brands for the leading edge in quality and innovation of their products. The Plus X Award with its seven quality seals and selected specific awards set the standard for the best products and are an unmistakable sign for brand quality.
Medisana is one of the leading specialists on the home healthcare market. For over 35 years, the German company has been committed to people's health with the motto "Your health in good hands." Medisana is a pioneer in the trend of mobile health management and provides future-oriented products for modern everyday life in an increasingly networked world. In the field of massage, the Neuss-based company is the German market leader. Medisana develops, markets, and sells products related to mobile health, health monitoring, wellness, sports, personal care, therapy and healthy homes to health-conscious consumers around the world.
About NanoVibronix, Inc.
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, New York, with research and development in Nesher, Israel, focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The Company's primary products include PainShield®, UroShield® and WoundShield®, all of which are portable devices suitable for administration at home without assistance of medical professionals. Additional information about NanoVibronix is available at: www.nanovibronix.com.
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with: (i) market acceptance of our existing and new products or lengthy product delays in key markets; (ii) negative or unreliable clinical trial results; (iii) inability to secure regulatory approval
s for the sale of our products ,; (iv) intense competition in the medical device industry from much larger, multinational companies ,; (v) product liability claims; (vi) product malfunctions; (vii) our limited manufacturing capabilities and reliance on subcontractor assistance; (viii) insufficient or inadequate reimbursements by governmental and/or other third party payers for our products; (ix) our ability to successfully obtain and maintain intellectual property protection covering our products; (x) legislative or regulatory reform impacting the healthcare system in the U.S. or in foreign jurisdictions; (xi) our reliance on single suppliers for certain product components, (xii) the need to raise additional capital to meet our future business requirements and obligations, given the fact that such capital may not be available, or may be costly, dilutive or difficult to obtain; and (xiii) our conducting business in foreign jurisdictions exposing us to additional challenges, such as, e.g., foreign currency exchange rate fluctuations, logistical and communications challenges, the burden and cost of compliance with foreign laws, and political and/or economic instabilities in specific jurisdictions. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at: http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise.
SOURCE NanoVibronix, Inc.